Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Biomed Pharmacother ; 155: 113675, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36115110

ABSTRACT

BACKGROUND: Breast cancer prevalence has been globally increasing, therefore, introducing novel interventions in cancer treatment is of a significant importance. The present study was designed to investigate the anti-cancer effect of Canagliflozin (CNG) in an experimental model of DMBA-induced mammary carcinoma in female rats. METHODS: 18 female rats were divided into three experimental groups: Normal control, DMBA control, DMBA+ CNG treated group. DMBA (7.5 mg/kg) was injected subcutaneously in the mammary cells twice weekly for 4 weeks and CNG (10 mg/kg) was orally administered daily for an additional 3 weeks while DMBA control rats only received the vehicle for 3 weeks. Tumors' weight and volume were measured, BRCA-1 and TAC were quantified in serum samples, mTOR, caspase-1, NFκB, IL-1ß, NLRP3, GSDMD and MDA were quantified in tumors' homogenates. RESULTS: CNG treatment increased the BRCA-1 expression, suppressed mTOR inflammatory pathway, attenuated tumor inflammatory mediators; NLRP3, GSDMD, NFκB, IL-1ß, suppressed the oxidative stress and inhibited tumor expression of the proliferation biomarker; Ki67. CONCLUSION: CNG modulated mTOR-mediated signaling pathway and attenuated pyroptotic, inflammatory pathways, suppressed oxidative stress and eventually inhibited DMBA-induced mammary carcinoma proliferation.


Subject(s)
Carcinoma , Mammary Neoplasms, Experimental , Rats , Female , Animals , 9,10-Dimethyl-1,2-benzanthracene/toxicity , Ki-67 Antigen/metabolism , Canagliflozin , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/prevention & control , Rats, Sprague-Dawley , NLR Family, Pyrin Domain-Containing 3 Protein , Signal Transduction , Caspase 1/metabolism , TOR Serine-Threonine Kinases/metabolism , Inflammation Mediators
2.
Naunyn Schmiedebergs Arch Pharmacol ; 390(10): 1061-1071, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28733879

ABSTRACT

Cancer refers to a disorder of cell proliferation that leads to tumor production. Cancer is usually treated by surgery, chemotherapeutic drugs, and radiation. Despite the presence of many anticancer drugs, cancer is still an uncontrolled disease and is a major cause of death worldwide. In addition, most anticancer drugs have severe side effects that can limit their use in some patients. This study aims to investigate the possible anticancer activity of two clinically used drugs: a natural antioxidant agent (salicin) and an antihyperlipidemic agent (fenofibrate) against two breast cancer models (in vivo EAC and in vitro MCF7) and the pancreatic cancer cell line (Panc-1).Our results have shown that both salicin and fenofibrate exerted an in vivo anticancer activity as evidenced by the decrease in tumor weight, tumor volume, CEA level, and reduced tumor cholesterol content through an antioxidant (reduced MDA level and increased GSH and catalase content) and an antiinflammatory activity (reduced TNF-∝ level). In addition, both salicin and fenofibrate were shown to be cytotoxic to MCF-7 and Panc-1 cell lines through activation of the caspase 3/7 apoptotic pathway.In conclusion, salicin and fenofibrate are promising anticancer drugs that are already used clinically with acceptable safety profile which can be incorporated into clinical trials to determine their possible application in cancer treatment.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Benzyl Alcohols/pharmacology , Carcinoma, Ehrlich Tumor/drug therapy , Fenofibrate/pharmacology , Glucosides/pharmacology , Tumor Burden/drug effects , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Benzyl Alcohols/therapeutic use , Carcinoma, Ehrlich Tumor/pathology , Cell Survival/drug effects , Cell Survival/physiology , Female , Fenofibrate/therapeutic use , Glucosides/therapeutic use , Humans , MCF-7 Cells , Mice , Tumor Burden/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...